On this page
What each program costs in North Carolina
The monthly price is all-in: the drug plus a membership when we have verified one. Compounded drugs are not FDA-approved.
| # | Program | Cheapest product | Plan | All in | Membership fee | Trustpilot | Checked | Seller site |
|---|---|---|---|---|---|---|---|---|
| 1 | Compounded Semaglutide | sale price | $39/mo | not verified | too few reviews | Visit | ||
| 2 | Compounded Semaglutide | 12-month plan, $588 up front | $49/mo | none | 3.9 (11,798 reviews) | Visit | ||
| 3 | Compounded Semaglutide | month to month | $59/mo | none | too few reviews | Visit | ||
| 4 | Compounded Semaglutide | 12-month plan, $828 up front | $69/mo | none | 4.6 (4,268 reviews) | Visit | ||
| 5 | Compounded Semaglutide | medication monthly, membership yearly | $75/mo | $199/yr, included | 4.8 (288 reviews) | Visit | ||
| 6 | Compounded Semaglutide | month to month | $79/mo | none | too few reviews | Visit | ||
| 7 | Compounded Semaglutide | month to month | $99/mo | none | 4.6 (5,235 reviews) | Visit | ||
| 8 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.3 (880 reviews) | Visit | ||
| 9 | Compounded Semaglutide | 12-month plan, $1,188 up front | $99/mo | none | 4.2 (218 reviews) | Visit | ||
| 10 | Compounded Semaglutide | 12-month plan, $1,260 up front | $105/mo | none | too few reviews | Visit | ||
| 11 | Compounded Semaglutide | 12-month plan, $1,698 up front | $141/mo | none | too few reviews | Visit | ||
| 12 | Semaglutide | month to month | $149/mo | none | too few reviews | Visit | ||
| 13 | Compounded Semaglutide | 12-month plan, $1,788 up front | $149/mo | none | 4.2 (777 reviews) | Visit | ||
| 14 | Microdosing Tirzepatide | 12-month plan, $2,028 up front | $169/mo | none | 4.0 (162 reviews) | Visit | ||
| 15 | Compounded Semaglutide | 2-month plan, $350 up front | $175/mo | none | 4.6 (1,084 reviews) | Visit | ||
| 16 | Compounded Oral Semaglutide Capsules | 6-month plan, $1,194 up front | $199/mo | none | too few reviews | Visit | ||
| 17 | Foundayo (brand orforglipron) | medication monthly, membership yearly | $208/mo | $59/mo, billed yearly, included | 4.6 (4,607 reviews) | Visit | ||
| 18 | Sublingual Semaglutide | month to month | $249/mo | none | 4.5 (17,622 reviews) | Visit | ||
| 19 | Compounded Semaglutide | month to month | $299/mo | none | too few reviews | Visit |
Does the North Carolina State Health Plan cover GLP-1s for weight loss?
The North Carolina State Health Plan stopped covering GLP-1 drugs such as Wegovy and Saxenda for weight loss on April 1, 2024. As of the Plan's October 2025 statement, restoring that coverage was still a negotiation with manufacturers, not coverage the Plan said was already back.
NC Department of State Treasurer
In January 2024 the State Health Plan Board of Trustees voted to end coverage of Wegovy and Saxenda for weight loss, effective April 1, 2024.
“In January, the State Health Plan Board of Trustees (Board) voted to end coverage of popular GLP-1 drugs like Wegovy and Saxenda for the purpose of weight loss starting on April 1, 2024, citing their high cost.”
https://www.nctreasurer.gov/news/press-releases/2024/04/22/treasurer-folwell-and-state-health-plan-issue-request-information-glp-1-drugs · read Oct 28, 2026
NC Department of State Treasurer
On October 7, 2025 the Plan said a new CVS Caremark agreement let it negotiate with GLP-1 manufacturers to potentially restore weight-loss coverage. The release does not say coverage had been restored.
“Additionally, this agreement gives the Plan the ability to negotiate directly with manufacturers of GLP-1s to potentially restore coverage of weight-loss medications to members.”
https://www.nctreasurer.gov/news/press-releases/2025/10/07/north-carolina-department-state-treasurer-announces-successful-negotiation-cvs-caremark · read Oct 28, 2026
What do North Carolina's big insurers publish on Wegovy and Zepbound?
Blue Cross NC
Blue Cross NC's commercial policy, version April 2025, publishes prior-authorization criteria for Wegovy and Zepbound. Coverage still requires the member's plan to include anti-obesity medication benefits.
Blue Cross NC
The April 2025 update of Blue Cross NC's anti-obesity policy names Wegovy and Zepbound and sets an initial approval of 180 days.
“April 2025: Criteria change (Zepbound): Updated Zepbound initial criteria for obstructive sleep apnea in adults with obesity. Updated duration of approval for Contrave, Qsymia, Saxenda, Wegovy, and Zepbound initial criteria to 180 days.”
https://www.bluecrossnc.com/providers/policies-guidelines-codes/commercial/um/pharmacy-benefit/updates/anti-obesity-agents-nc-standard · read Oct 28, 2026
Blue Cross NC
Since January 2023, Blue Cross NC has required the member to have anti-obesity medication benefits before this policy applies.
“Members required to have anti-obesity medication coverage benefits.”
https://www.bluecrossnc.com/providers/policies-guidelines-codes/commercial/um/pharmacy-benefit/updates/anti-obesity-agents-nc-standard · read Oct 28, 2026
Getting a GLP-1 online in North Carolina
The North Carolina Board of Pharmacy says compounding copies of approved tirzepatide products is no longer allowed, and it restates FDA's finding that the semaglutide injection shortage had resolved, with enforcement discretion ending April 22, 2025 for pharmacies and May 22, 2025 for outsourcing facilities.
North Carolina Board of Pharmacy
The Board's compounding FAQ says copies of approved tirzepatide products are no longer allowed.
“With the litigation’s end, compounding copies of approved tirzepatide products is no longer allowed.”
https://www.ncbop.org/faqs/general-pharmacy-faqs.html · read Oct 28, 2026
North Carolina Board of Pharmacy
The same answer says FDA found the semaglutide injection shortage resolved and set an end to enforcement discretion in April and May 2025.
“On February 21, 2025, FDA issued a statement concerning compounded semaglutide products. FDA has determined that shortages of semaglutide injection products have resolved. To avoid unnecessary disruption to patient treatment, FDA announced that it would not take action against compounders for violations of the Food and Drug Cosmetic Act until the following dates: For state-licensed 503A compounding pharmacies, sixty (60) days from the February 21 statement – April 22, 2025. For 503B outsourcing facilities, ninety (90) days from the February 21 statement – May 22, 2025.”
https://www.ncbop.org/faqs/general-pharmacy-faqs.html · read Oct 28, 2026
Does North Carolina Medicaid cover GLP-1s for weight loss?
Covered, with conditions
NC Medicaid covers Wegovy and Zepbound for weight management with prior approval, after ending that coverage on October 1, 2025 and restoring it on December 12, 2025. Read from state documents Nov 6, 2026.
What North Carolina Medicaid's documents say about each drug for weight loss. Read Nov 6, 2026. North Carolina Department of Health and Human Services, Division of Health Benefits.
WegovyYes
Prior approval. Adults with BMI 30 or higher, or BMI 27 or higher with a weight-related condition. Ages 12 to 17 have separate BMI rules. Lifestyle program required.
“Effective Dec. 12, 2025, coverage for GLP-1s for the treatment of obesity will be reverted to the coverage available as of Sept. 30, 2025.”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Dec 12, 2025 · read Nov 6, 2026
“The beneficiary is overweight or obese and is using the requested agent for weight management and ALL of the following”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Aug 1, 2024 · read Nov 6, 2026
“Wegovy® Pen/Tablet liraglutide Pen/5-pak (generic Saxenda®)”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Oct 1, 2026 · read Nov 6, 2026
ZepboundYes
Prior approval for adults 18 and older, BMI 30 or higher, or BMI 27 or higher with a weight-related condition. Vial removed from the PDL. The December 2025 notice required trying Wegovy first; the October 2026 list does not settle whether that still applies.
“Effective Dec. 12, 2025, coverage for GLP-1s for the treatment of obesity will be reverted to the coverage available as of Sept. 30, 2025.”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Dec 12, 2025 · read Nov 6, 2026
“The beneficiary is overweight or obese and is using the requested agent for weight management and ALL of the following”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Aug 1, 2024 · read Nov 6, 2026
“Removed Zepbound ® (tirzepatide) Vial in the GLP-1 Receptor Agonists indicated for the treatment of obesity”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Sep 4, 2026 · read Nov 6, 2026
OzempicNot confirmed
The only diabetes criteria text found is a 2023 public comment draft (media/13321), which cannot support an answer, and the NCTracks GLP-1 criteria PDF returned 404. The September 2025 bulletin keeps diabetes coverage but does not state the limits for this drug.
MounjaroNot confirmed
The only diabetes criteria text found is a 2023 public comment draft (media/13321), which cannot support an answer, and the NCTracks GLP-1 criteria PDF returned 404. The September 2025 bulletin keeps diabetes coverage but does not state the limits for this drug.
This reports what the documents say. It is not medical or legal advice: your plan and your prescriber decide.
What changed, and when
- Nov 6, 2026 · This pageFirst read from North Carolina Department of Health and Human Services, Division of Health Benefits documents. KFF's January 2026 map listed this program as covered; the documents we read agree.
- Dec 12, 2025 · Policy changeRestored coverage of GLP-1 drugs for obesity.
“Effective Dec. 12, 2025, coverage for GLP-1s for the treatment of obesity will be reverted to the coverage available as of Sept. 30, 2025.”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Dec 12, 2025 · read Nov 6, 2026
- Oct 1, 2025 · Policy changeEnded coverage of GLP-1 drugs for obesity.
“Effective Oct. 1, 2025, NC Medicaid coverage for GLP-1s for the treatment of obesity will be discontinued.”
NC Medicaid, NCDHHS Division of Health Benefits · Effective Oct 1, 2025 · read Nov 6, 2026
Weight loss
Covered, read Nov 2026
Type 2 diabetes
Required in every state
Heart risk, sleep apnea
Required (Wegovy, Zepbound)
Prior authorization
Typical when covered
Wegovy, Zepbound, Saxenda, 2025
228,314 prescriptions
Ozempic and Mounjaro, 2025
215,474 prescriptions
Neighbours covering weight loss
2 of 4
Federal law lets each state decide whether Medicaid pays for drugs used for weight loss, while drugs approved for diabetes must be covered. A state document may not settle every plan; if your North Carolina Medicaid coverage comes through a managed care plan, its formulary can differ, so ask the plan before you fill.
For comparison, a dated secondary source: KFF's January 2026 map listed North Carolina Medicaid as "covered" for GLP-1s for obesity under fee-for-service. North Carolina dropped GLP-1 coverage in October 2025 over a budget stalemate and reinstated it in December 2025.
The BALANCE model
CMS’s BALANCE model lets state Medicaid programs add GLP-1s for weight management at a negotiated price. States could join on a rolling basis from May 1, 2026 through January 1, 2027, and the state application deadline was July 31, 2026. We could not find a published list of the states that joined, so this page does not say whether North Carolina Medicaid did. Ask your plan. Either way your cost stays at Medicaid’s nominal copay, which BALANCE does not change.
The national picture, coupons and patient assistance: does Medicaid cover GLP-1s.
How many GLP-1s does North Carolina Medicaid pay for?
484,401 GLP-1 prescriptions in 2025, 5th of the 50 states and DC, with $570.0 million reimbursed before rebates. Counting the share other payers covered, $589.7 million.
Prescriptions, 2025
484,401
5th of 51
Medicaid paid
$570.0M
5th of 51, before rebates
Per prescription
$1,177
$1,051 nationally
Weight-loss brands
47%
11th highest share of 51
CMS State Drug Utilization Data 2025, updated Jul 13, 2026, fee-for-service and managed care, before rebates. North Carolina is highlighted. CMS publishes this comparison as one year, not a trend.
Wegovy, Zepbound and Saxenda, the brands approved for weight management, were 47% of North Carolina Medicaid's GLP-1 prescriptions in 2025 (228,314). Across the 13 states KFF lists as covering GLP-1s for obesity, the median share was 52%; across the other 38, 2.3%. Where weight loss is not covered, those brands are mostly filled for the uses Medicaid must cover, such as heart risk and sleep apnea. Wegovy was North Carolina Medicaid's most filled GLP-1.
| Brand | Prescriptions | Share | Medicaid paid | Per Rx |
|---|---|---|---|---|
| Wegovyapproved for weight management | 203,087 | 42% | $270.7 million | $1,333 |
| Ozempic | 156,494 | 32% | $169.1 million | $1,081 |
| Mounjaro | 58,980 | 12% | $62.8 million | $1,064 |
| Trulicity | 34,349 | 7.1% | $35.6 million | $1,035 |
| Zepboundapproved for weight management | 25,111 | 5.2% | $25.3 million | $1,008 |
| Rybelsus | 4,309 | 0.9% | $5.2 million | $1,209 |
| Liraglutide (generic) | 1,121 | 0.2% | $586,541 | $523 |
| Victoza | 685 | 0.1% | $498,116 | $727 |
| Bydureon | 126 | 0.0% | $121,344 | $963 |
| Saxendaapproved for weight management | 116 | 0.0% | $136,774 | $1,179 |
| Byetta | 23 | 0.0% | $19,806 | $861 |
Source: CMS State Drug Utilization Data 2025, updated Jul 13, 2026, all four quarters, fee-for-service and managed care. Before rebates. CMS suppresses rows under 11 prescriptions, so small brands are undercounted slightly. Every state ranked: prescriptions and spending.
Which FDA-registered outsourcing facilities are in North Carolina?
FDA's register of 503B outsourcing facilities, updated Nov 17, 2026, lists 1 in North Carolina. The register does not say which, if any, supplies a program on this page.
- Apothecary Pharma, LLC, Cary. Registered since Sep 7, 2024; last FDA inspection Sep 2, 2026.
On Medicare in North Carolina?
Medicare’s temporary GLP-1 Bridge works the same in every state: a $50 copay for a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who meet its weight and health rules.
medicare.gov
“You’ll pay a $50 copayment to the pharmacy for a one-month supply (either 28 or 30 days, depending on drug).”
https://www.medicare.gov/coverage/weight-loss-drugs · read Nov 14, 2026
North Carolina and the states around it
Medicaid’s weight-loss answer (the state’s own documents where we have read them, otherwise KFF, January 2026) and the partner programs that ship there, priced the same way as above.
2 of the 4 states next to North Carolina cover GLP-1s for weight loss through Medicaid: Tennessee and Virginia. None has a lower cash floor than North Carolina's $39.
| State | Medicaid, weight loss | Ship there | Cheapest that ships there |
|---|---|---|---|
| North Carolina | Covered | 19 | $39/mo |
| Georgia | Not covered | 18 | $39/moWellmedr |
| South Carolina | Not covered in part | 18 | $39/moWellmedr |
| Tennessee | Covered | 18 | $39/moWellmedr |
| Virginia | Covered | 19 | $39/moWellmedr |






















